advertisement

---

Fukushima A 11

Showing records 1 to 11 | Display all abstracts from Fukushima A

80580 Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial
Sakamoto E
Scientific reports 2019; 9: 3755

---

80453 Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil
Saito H; Kagami S
Journal of Glaucoma 2019; 28: 289-293

---

80580 Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial
Ishida W
Scientific reports 2019; 9: 3755

---

80453 Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil
Mishima K
Journal of Glaucoma 2019; 28: 289-293

---

80580 Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial
Sumi T; Kishimoto T
Scientific reports 2019; 9: 3755

---

80453 Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil
Mataki N
Journal of Glaucoma 2019; 28: 289-293

---

80580 Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial
Tada K
Scientific reports 2019; 9: 3755

---

80453 Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil
Fukushima A
Journal of Glaucoma 2019; 28: 289-293

---

80580 Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial
Fukuda K
Scientific reports 2019; 9: 3755

---

80453 Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil
Araie M
Journal of Glaucoma 2019; 28: 289-293

---

80580 Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial
Yoneda T; Kuroiwa H; Terao E; Fujisawa Y; Nakakura S; Jian K; Okumichi H; Kiuchi Y; Fukushima A
Scientific reports 2019; 9: 3755

---